Teduglutide

Label

ClassGLP-2 analog

Typical routes in papersDaily SC on label

Half-life context~1–2 hours, daily dosing

EvidenceFDA-approved for short-bowel syndrome

What it is

Teduglutide is a GLP-2 analog that tells the remaining intestine to grow more absorptive surface. It is a short-bowel drug (Gattex), not a gym peptide.

Benefits in plain language

What researchers and reference users usually mean when they talk about this compound. These are study themes and common claims — not a promise that it will do this in you.

On-label benefit: fewer liters of IV nutrition for people with short bowel.
The “grow the gut lining” idea is why BPC/KPV crowds sometimes name-drop GLP-2. They are not interchangeable.
Polyp surveillance exists because growth signals in the gut are not a free lunch.

If a branded, FDA-approved product exists, that label is the only dose that is actually authorized. Research-chemical vials are a different object.

Mechanism of action

GLP-2 receptor agonism increases intestinal villus height, blood flow, and barrier function.

Possible side effects / caveats

Fluid overload, stoma enlargement, gallbladder/pancreas warnings, theoretical neoplasm risk — read the insert.

Protocol ranges

Source tier	Amount	Frequency / duration	Notes
Label	0.05 mg/kg	Once daily SC	Short-bowel product; weight-based

Numbers below and above are literature or community pointers, not a treatment plan. Approved products, when they exist, follow the official label — not a research vial.